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The mammalian target of rapamycin (mToR), a serine
(Ser)/threonine (Thr) kinase, plays an important role in multi-
ple myeloma (MM) since it is involved in the phosphoinositol-
3 kinase (PI3K)-AKT pathway activated by essential growth
and survival factors such as interleukin-6 (IL-6) as well as the
insulin-like growth factor-1, by mutated oncogenes such as
Ras, by vascular endothelial growth factor or by loss of the
phosphatase and tensin homolog (PTEN).1-6 mToR is part of the
mToR1 complex (mToRC1), which is controlled by proline-
rich AKT substrate of 40 kDa (PRAS40) and tuberous sclerosis
(TSC)2, both inhibited by activated AKT (when phosphorylat-
ed on Thr308 and Ser473). The mToRC1 acts as an ATP and
amino acid sensor to balance nutrient availability and cell
growth by regulating metabolism, translation and autophagy.7-
12 Rapamycin, a bacterial product from Streptomyces hygroscopi-
cus with antifungal, immunosuppressive and anti-tumor activ-
ity, is first in a class of allosteric mToR inhibitors (rapa-
logues).13,14 Preclinical data showed the anti-myeloma activity
of these drugs alone or in combination with dexamethasone.15-
18 Thus, it was tempting to test the anti-myeloma activity of
mToR inhibitors in MM patients who had failed to benefit
from the available treatment options extended in the last
decade by the introduction of proteasome inhibitors such as
bortezomib and immunomodulating drugs.19-22
The rapalogue everolimus (RAD001) is approved for
immunosuppression and for the treatment of several malig-
nancies such as metastatic renal cell cancer, gastroenteropan-
creatic neuroendocrine tumor and subependymal giant cell
astrocytoma.23-30 In this investigator-initiated phase I study the




The trial CRAD001C2455 was designed as an open-label, multi-
center phase I trial of continuous, escalating doses of everolimus once
daily in patients aged ≥18 years who had relapsed or refractory MM
after two prior treatment lines. The primary objective was to deter-
mine the maximum tolerated dose of everolimus and dose-limiting
toxicities. Secondary objectives included an assessment of the tolera-
bility and clinical activity of everolimus. At least three patients were
to be included at each dose level until the maximum tolerated dose
was reached. The treatment was planned for six 28 day cycles if no
progressive disease or dose-limiting toxicity was observed. However,
an additional treatment with study drug was allowed for patients
achieving clinical benefit after six cycles.
Patients
Adult patients with relapsed or refractory MM of Salmon and Durie
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The mammalian target of rapamycin plays an important role in multiple myeloma. The allosteric mammalian tar-
get of rapamycin inhibitor everolimus has long been approved for immunosuppression and has shown activity in
certain cancers. This investigator-initiated phase I trial explored the use of everolimus in relapsed and/or refractory
multiple myeloma patients who had received two or more lines of prior treatment. Following a dose-escalation
design, it called for a fixed dose of oral everolimus. Blood drug levels were monitored and the biological activity
of everolimus was evaluated in bone marrow. Seventeen patients were enrolled (age range, 52 to 76 years). All had
been previously treated with stem cell transplantation and proteasome inhibitors and almost all with
immunomodulatory drugs. No dose-limiting toxicity was observed and the intended final daily dose of 10 mg was
reached. Only one severe adverse event was assessed as possibly related to the study drug, namely atypical pneu-
monia. Remarkably few infections were observed. Although the trial was mainly designed to evaluate feasibility,
anti-myeloma activity, defined as clinical benefit, was documented in ten of 15 evaluable patients at every dose
level including eight patients with stable disease, one patient with minor remission and one with partial remission.
However, the median time to progression was 90 days (range, 13 to 278 days). The biomarker study documented
on-target activity of everolimus in malignant plasma cells as well as the microenvironment. The observed respons-
es are promising and allow further studies to be considered, including those testing combination strategies address-
ing escape pathways. This trial is registered with EudraCT number 2006-002675-41. 
Activity of everolimus (RAD001) in relapsed and/or refractory 
multiple myeloma: a phase I study
Andreas Günther,1 Philipp Baumann,2 Renate Burger,1 Christian Kellner,1 Wolfram Klapper,3 Ralf Schmidmaier,2
and Martin Gramatzki1
1Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University of Kiel, Germany; 2Medizinische
Klinik und Poliklinik IV, Klinikum der Ludwig-Maximillians-Universität München (LMU), Germany; and 3Division of Hematopathology,
Institute of Pathology, University of Kiel, Germany
ABSTRACT
stage ≥ II after failure of at least two prior treatment regimens were
enrolled. The study was designed in accordance with the
International Conference on Harmonisation (ICH) Harmonised
Tripartite Guidelines for Good Clinical Practice, with applicable
local regulations and the ethical principles of the Declaration of
Helsinki. The protocol was approved by the Institutional Review
Board/Independent Ethics Committee/Research Ethics Board at
each study site, and informed consent was obtained from all
patients (EudraCT number: 2006-002675-41).
Key inclusion criteria were WHO performance status ≤ 2, meas-
urable disease markers, adequate bone marrow function, and ade-
quate liver function. 
Pharmacokinetic analyses and drug adjustment
The everolimus concentrations in whole blood were deter-
mined by a validated liquid chromatography method (Central
Laboratory of the University Hospital of Göttingen, Germany). In
cohort 1 of the dose escalation phase, the starting dose was 5 mg
everolimus, which was followed by cohorts given doses of 7.5 mg
and 10 mg. If a patient showed a significant deviation from the
intended blood drug level (defined as ± 50%), the dose had to be
adjusted without, however, exceeding the dose of 10 mg/day. To
investigate the correlation of the median achieved drug level and
the M protein response, the Pearson product-moment correlation
coefficient was calculated (2-tailed significance, SPSS 13).
Bone marrow assessment
Bone marrow aspirates and biopsies were performed during
screening, 28 days into treatment, at the end of study and when
clinically indicated. Immunohistochemical staining for mToR, for
the downstream targets 4E-binding protein 1 and phosphorylated
S6 ribosomal protein (S6) were performed using antibodies from
Cell Signaling (Danvers, USA), as described previously.31
Effect on the immune system
To elucidate the effect of everolimus on the immune system of
MM patients the levels of the not involved immunoglobulin class-
es were determined by turbidimetric measurement (Cobas c sys-
tem, Roche Diagnostics, Mannheim, Germany) and lymphocyte
subsets were assessed by FACS staining as described previously
(antibodies provided by Beckman Coulter, Krefeld, Germany).32
The values determined at baseline were compared to the last val-
ues achieved during treatment and tested for significant changes
using the paired two-tailed t-test (SPSS 13). In two patients under
treatment, cytotoxic activities of natural killer (NK) cells were
determined (compared to those of a healthy volunteer) in a stan-
dard 51Cr release assay performed as described previously.33
Results
Patients
Seventeen patients (13 males, 4 females) aged from 52 to
73 years with relapsed or refractory MM were enrolled in
this interventional clinical trial (for details see Table 1).
They had received a median of three (range, 2 to 9) prior
lines of therapy and all had undergone one or more autol-
ogous stem cell transplant; one patient had also undergone
allogeneic stem cell transplantation. Sixteen of 17 patients
had received prior treatment with both bortezomib and
immunomodulatory drugs. In addition, most patients
received some form of radiation therapy during the course
of their disease.
The initial cohort treated with 5 mg everolimus had to
be expanded with two additional patients due to one
screening failure and one patient in whom the everolimus
dose had to be increased to 10 mg daily according to pro-
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Table 1. Patients’ characteristics.
Patient Age Sex S&D ISS Type Cytogenetic abnormality LoT Auto/ PT
allo
001-001 71 M IIIA III BJ λ del11q, del13q 3 2/0 B/I
001-002 59 M IIIA I IgG  κ +11 3 2/0 B/I/RT
001-003* 55 M IIIA III IgG λ None 4 2/1 B/I
001-004 52 M IIIA I IgA κ del13q, t (4:14) 5 2/0 B/I
001-005 54 M IIIA III IgA κ del21q, +11 3 2/1 B/I/RT
001-006 61 M IIIA I IgG  κ +11 3 1/0 B
001-007 69 M IIIA I IgG  κ +21 5 2/0 B/I
001-008 60 M IIIA III IgG  κ del13q, t (4:14) 5 2/0 B/I/RT
001-009 61 M IIIA III IgA κ del11q, +11 5 2/0 B/I
001-010 63 F IIIA I IgG  κ del13q, +21 2 2/0 B/I
001-011 67 M IIIA I IgA κ del13q, t(4;14) 3 2/0 B/I
001-012 70 F IIIA I IgG λ del13q, +11 3 2/0 B/I/RT
001-013** 69 F IIA I IgG  κ Complex aberrant 9 2/0 B/I/RT
001-014 73 M IIIA I IgG  κ n.a. 2 2/0 B/I/RT
003-001 60 M IIIA III IgG  κ n.a. 3 4/0 B/I/RT
003-002 59 M IIIA I IgG  κ n.a. 3 4/0 B/I/RT
003-003 76 F IIIA II IgG  κ n.a. 3 2/0 B/I/RT
*Screening failure;**Primary extra-medullary disease; S&D: Salmon and Durie stage; ISS: International Staging System; LoT.: prior lines of treatment, Auto/allo: previous autolo-
gous/allogeneic transplantation of hematopoietic progenitor cells; PT: previous treatment with bortezomib (B), immune modulatory drugs (I) or radiotherapy (RT), n.a. = not avail-
able; BJ: Bence-Jones MM.
tocol to achieve the intended blood level. While the
patients in cohort 2 were given 7.5 mg everolimus as
planned, three patients in the third cohort of 10 mg were
replaced because of early termination of the trial due to
progressive disease or withdrawal of consent in one case.
In total three patients, one at the dose level of 7.5 mg and
two patients receiving 10 mg completed the planned 6
months of study treatment. 
Pharmacokinetic analysis
The median blood level achieved in the first two cohorts
was in the intended range, whereas six of nine of the third
cohort did not achieve the intended level (Online
Supplementary Data). However, at this highest planned
dose level no dose changes were performed. Notably, the
median blood level of all three cohorts was comparable at
day 28 and no correlation between dose and blood levels
was shown. 
Safety
Adverse events were mostly mild to moderate (Table 2).
Thrombocytopenia was the most frequent hematologic
adverse event, followed by leukopenia and anemia.
Metabolic changes as well as elevated muscle and liver
enzymes were the most frequent non-hematologic events
followed by several mostly mild gastrointestinal events.
Interestingly, infectious complications and bleeding were
rare events and when they did occur, they were mild.
According to protocol, if relevant toxicity was observed,
the everolimus dose had to be reduced or the drug with-
held for up to 7 days at the investigator’s discretion.
However, none of the adverse events led to dose reduction
or permanent withholding of the study drug. During the
trial eight serious adverse events were reported, all being
serious because hospitalization was required. However,
only one serious adverse event, namely atypical pneumo-
nia (extra-medullary MM in the lung was also discussed),
was considered by the investigators to be possibly related
to the study drug, although it did not resemble a drug-
induced pneumonitis. Most of the other serious adverse
events were caused by progressive disease or were clearly
related to other causes such as an allergic reaction to
trimethoprim/sulfamethoxazole or pain due to
osteonecrosis of the jaw. Pulmonary embolism occurred in
one patient without a previous history of thromboembolic
events.
Determination of maximum tolerated dose
By protocol dose-limiting toxicity was defined as fol-
lows: any febrile neutropenia, any grade ≥3 neutropenia or
grade 4 thrombocytopenia lasting more than 7 days, any
grade ≥3 pneumonitis, any grade 4 non-hematologic
events, and any two or more events requiring a reduction
in the dose of everolimus or any adverse event resulting in
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Table 2. Tolerability of everolimus.
Adverse events (%) Maximal Grade (CTC)
(only, if occurred in ≥ 5 of patients) 1 2 3 4 All
Thrombocytopenia 4 (25) 4 (25) 5 (31) 1 (6) 14 (88)
Leukopenia 2 (13) 5 (31) 4 (25) 11 (69)
Neutropenia 5 (31) 4 (25) 9 (64)
Epistaxis 8 (50) 8 (50)
Hypertriglyceridemia 5 (31) 2 (13) 1 (6) 8 (50)
Respiratory  infection 3 (21) 5 (31) 8 (50)
Anemia 1 (6) 5 (31) 1 (6) 7 (44)
Alanine aminotransferase elevated 6 (38) 1 (6) 7 (44)
Creatinine phosphokinase elevated 4 (25) 2 1 (6) 7 (44)
Facial flush 5 (31) 1 (6) 6 (38)
Aspartate aminotransferase elevated 5 (31) 1 (6) 6 (38)
Hyperglycemia 4 (25) 1 (6) 1 (6) 6 (38)
Lymphocytopenia 1 (6) 5 (31) 6 (38)
Diarrhea 5 (31) 5 (31)
Headache 4 (25) 1 (6) 5 (31)
Hypophosphatemia 4 (25) 1 (6) 5 (31)
Increase of lactate dehydrogenase 5 (31) 5 (31)
Serious adverse events Patient Serious due to Related to everolimus
Collapse due to pain (osteonecrosis of the jaw) 001-001 Hospitalization No
Pulmonary embolism 001-001 Hospitalization No
Paresis (spinal tumor) 001-008 Hospitalization No
Allergic reaction against trimethoprim/sulfamethoxazole 001-009 Hospitalization No
Hyperviscosity 003-001 Hospitalization No
Hyperviscosity and renal failure 003-002 Hospitalization No
Atypical pneumonia (or pulmonary extra-medullary myeloma) 003-003 Hospitalization Possible
more than a 4-week interruption or delay of study treat-
ment. Since none of these was observed, the highest test-
ed dose of 10 mg daily (or above) was considered to be the
maximum tolerated dose.
Immunomodulation
Despite everolimus acting as an immunosuppressive,
the rate of infectious complications was comparable to
that reported with other treatment regimens used in
patients with advanced MM. No significant alteration of
lymphocyte subsets was noted during treatment (Online
Supplementary Data). Functional tests of NK cells did not
reveal differences in comparison to controls (Figure 1A).
To evaluate immunosuppressive effects of everolimus on
normal immunoglobulin levels, non-involved
immunoglobulin classes were monitored. While most
patients had secondary antibody deficiency at baseline,
slight declines of IgM and IgG, but not of IgA, were noted
(Figure 1B). 
Efficacy and pharmacokinetics
Fifteen patients in the dose escalation phase were avail-
able for the planned efficacy assessment every 4 weeks or
showed early progressive disease within the first cycle
(two cases). The median time to progression was 90 days
(range, 13 to 278 days). The clinical response of all patients
is shown in Figure 2A. The majority of patients (10 out of
15; 67%) achieved a clinical benefit during the trial. One
patient (7 %) had a partial remission after four cycles of
treatment. Bone marrow biopsy revealed that reduction of
M-protein levels in the serum correlated with a decrease in
malignant plasma cells. Another patient (7%) in the first
cohort diagnosed with Bence-Jones MM qualified for a
minor response with a greater than 50% reduction of uri-
nary M protein. Eight patients (80%) achieved stable dis-
ease (for details see also Online Supplementary Data). Three
of 15 patients reached the endpoint of the study at 6
months with stable disease. One of these remained under
treatment for 278 days until progression occurred.
Therefore, based on the pre-defined efficacy criteria,
everolimus was found to be active with good tolerability.
The drug levels achieved in the blood showed consider-
able intra-individual variability, leading to comparable
blood levels in all cohorts. Although the patient who
achieved a partial response showed a rather high blood
level, no correlation between blood level and clinical effi-
cacy was established (Figure 2B). In addition, no signifi-
cant association was found between the median
everolimus blood level and the achieved M-protein
response (Pearson r = -0.07, P=0.81). 
Biomarker analysis
In order to access biomarkers for everolimus activity, the
phosphorylation of key proteins in the mToR pathway,
particularly mToR, 4EBP1 and S6 protein, was investigat-
ed. The biopsies at baseline showed a wide variety of acti-
vation of the pathway in the tumor cells (Figure 2C).
Irrespectively of the dose level and the response to treat-
ment, mToR phosphorylation was abolished in all biop-
sies obtained under treatment. However, the downstream
targets 4EBP1 (Figure 2D) and S6 showed residual phos-
phorylation in plasma cells as well as in bystander cells
(see also Online Supplementary Data for immunohistology). 
Discussion
Since the mToR pathway plays a crucial role in MM
pathophysiology the purpose of this trial was to evaluate
tolerability as well as the clinical benefit of the oral rapa-
logue everolimus in relapsed and/or refractory MM. The
trial showed that the drug had an acceptable safety profile
in this heavily pretreated group of patients. The rate of
infections was within the expected range. Pulmonary
embolism was observed in a single case. Since throm-
boembolism due to other reasons is not infrequent in MM,
a relationship with the study drug could not be firmly
established.
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Figure 1. The NK cells of two MM patients treated at the highest dose level (everolimus 10 mg daily) were compared to NK cells of a healthy
donor regarding their ability to lyse K562 cells (A, values represent the mean of triplicate experiments). No alterations in NK cell function were
observed (E:T = effector to target cell ratio). The immunoglobulin levels not involved in myeloma disease were monitored to measure the
impact of everolimus on normal B and plasma cells (B). The medians of immunoglobulin levels of informative patients at baseline (BL) and
at the end of the treatment (last available value, LV) are shown. Bars indicate minimal and maximal values, dotted lines the range of normal
values (ULN= upper limit of normal; LLN= lower limit of normal). Most patients had secondary antibody deficiency. The level of IgM declined
significantly over the treatment period (paired two-tailed t-test: P=0.029; * indicates statistical significance), while the decline of IgG was of
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The most frequent toxicities were thrombocytopenia
and leukopenia, gastrointestinal events and metabolic
changes. All of those were manageable, without any treat-
ment changes due to side effects. In a recent trial in
patients with renal cancer a proportional absorption of
everolimus was found.34 In our study, no clear correlation
was observed between everolimus dose and serum drug
levels achieved, perhaps because of the higher rate of anti-
infectious prophylaxis used in MM patients interacting
with drug metabolism or the limited patient number.
Since the main objective of the trial was to assess the
tolerability of everolimus, the efficacy data should be
viewed with caution. Despite these limitations the anti-
myeloma activity of everolimus was considerable: one
patient achieved a partial remission, one had a minor
response, and eight patients were clinically stable for up to
9 months. However, the median time of 90 days until pro-
gression indicates that monotherapy may be insufficient
for long-term control of advanced disease. The rapalogue
temsirolimus administered intravenously had previously
also shown some activity in patients with advanced MM
with a trend for better outcome in patients achieving high-
er drug levels.35 In our trial such a correlation could not be
established, although the patient with the best response
did have a rather high level of everolimus in the blood.
The weak dose-efficacy relationship of rapalogues in MM
might be explained by our observation that mToR activa-
tion in plasma cells was blocked even at the lowest dose
level. 
Inhibition of mToRC1 induces negative feedback loops,
such as inhibition of insulin receptor substrate by p70/S6
kinase.36,37 The evaluation of bone marrow during
everolimus treatment revealed a reduction but not abroga-
tion of the mToR downstream target 4EBP1 and S6 pro-
tein. This was irrespective of the dose level and despite
abolished mToR phosphorylation. In vitro experiments
showed that rapalogues failed to block cell growth com-
pletely even at high doses.17,38 However, the observed
activity of everolimus shows that mToRC1 is an essential
target in myeloma patients. Notably, activation of the
ToRC2 pathway by overexpression of DEP domain con-
taining mTOR interacting protein (DEPTOR)39 or activa-
tion of the ERK pathway may limit the dependency of
PI3K and mToRC1.40 The observed down-regulation of the
Everolimus in relapsed/refractory myeloma
haematologica | 2015; 100(4) 545
Figure 2. The waterfall plot shows the best response at time of assessment of the 12 available patients (A). The shading of the bars indicates
the different drug level cohorts: white is cohort 1 (5 mg), light gray cohort 2 (7.5 mg) and dark gray cohort 3 (10 mg). Black frames represent
serum M protein, black spotted frames total IgA (in cases without measurable serum M protein) and a gray frame represents urinary M protein
as a disease marker. Seven patients had clinical benefit, achieving stable disease (#), minor response (ǂ) or partial response (§). Five patients
showed progressive disease as defined by IMWG criteria (*), early withdrawal due to hyperviscosity (**) or growing spinal tumor (***). The
everolimus blood levels of patients (average of all measurements in a particular patient) grouped according to the best clinical status
achieved (B). Although the patient with a partial response had the second highest blood level, the data show no obvious correlation between
drug level and efficacy as indicated by comparable median blood levels for all groups [white diamond: dose level 1 (5 mg daily), gray quad-
rangle: dose level 2 (7.5 mg daily), dark gray circle: dose level 3 (10 mg daily)]; PD=progressive disease, SD=stable disease, MR= minor
response, PR= partial response). Bone marrow was stained for the phosphorylated forms of mToR (C) and 4EBP1 (D) demonstrating a wide
variety in activation of the pathway in plasma cells at baseline (dark gray bars). However, under treatment phosphorylation of mToR was abol-
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mToR pathway in bystander cells may have contributed
to the clinical activity of everolimus, since the
PI3K/AKT/mToR pathway plays a critical role in osteo-
clasts, possibly supporting the malignant plasma cells.41
The anti-angiogenic activity of rapalogues, via inhibition
of vascular endothelial growth factor, also has to be taken
into account.42
The rate of adverse events was low in this highly pre-
treated group of patients suggesting that everolimus
could potentially be combined with other drugs. As an
alternative, catalytic mToR kinase inhibitors block the
signaling of both mToR complexes also affecting the
mToRC2- dependent AKT activation. Notably, this class
of drugs showed greater anti-myeloma activity in vitro
when compared to rapalogues.38,43 However, in contrast
to rapalogues these compounds activate the ERK path-
way as a feedback loop that may limit activity.44
However, current data suggest that the combination of
PI3 kinase inhibitors added to rapalogues could be useful
given that the feedback loop of S6 protein to PI3K will
drive tumor cells in dependency on this pathway.45
Another rationale is to explore synergistic activity in vitro,
similar to that of the combination of rapalogues and his-
tone deacetylase inhibitors such as panobinostat.46
However, in a phase I trial combining everolimus with
panobinostat in lymphoma patients, severe thrombocy-
topenia occurred.47 Recently, based on in vitro synergism,48
the combination of everolimus and lenalidomide was
explored in a phase I trial and was found to have prom-
ising activity and acceptable tolerability in patients with
relapsed MM.49 Interestingly, weekly bortezomib com-
bined with temsirolimus showed promising activity in
relapsed MM, with responses in patients who had been
refractory to prior bortezomib-containing regimens.50
Since everolimus as a single agent showed promising
activity, with a limited rate of side effects, in relapsed
and/or refractory MM patients, efforts should be made to
evaluate optimal combination partners to enhance the
anti-myeloma activity and to target the PI3K-AKT-mToR
signaling network at multiple sites.
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